The present invention concerns prodrugs of mexiletine (and mexiletine's active metabolite) pharmaceutical compositions containing such prodrugs. Methods for treating myotonic conditions, while reducing the inherent adverse GI side effects associated with mexiletine, increasing the bioavailability of mexiletine, and improving the pharmacokinetic reproducibility of mexiletine with the aforementioned prodrugs are also provided.
本发明涉及
美西律定(以及
美西律定的活性代谢物)的前药以及含有这些前药的药物组合物。还提供了治疗肌张力不良症的方法,同时减少与
美西律定相关的固有不良胃肠副作用,增加
美西律定的
生物利用度,并改善
美西律定的药代动力学可重复性。